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Defi  ning pluripotent stem cells
Discovery of pluripotent stem cells - embryonal carcinoma 
cells
Pluripotency is the potential of stem cells to give rise to 
any cell of the embryo proper. Th  e study of pluripotent 
stem cells from both mouse and human began with the 
study of teratocarcinomas, germ cell tumours that occur 
predominantly in the testis and constitute the most 
common cancer of young men. In 1954, Stevens and Little 
[1] found that males of the 129 mouse strain developed 
testicular teratocarcinomas at a signiﬁ   cant rate. Th  is 
ﬁ   nding opened the way for detailed studies of these 
peculiar cancers, which may contain a haphazard array of 
almost any somatic cell type found in the developing 
embryo [2]. Th   e stem cells of these tumours are embryonal 
carcinoma (EC) cells, which express charac  teristics, 
including a developmental potential, similar to those of the 
inner cell mass (ICM) of the early embryo [3]. Experience 
with these pluripotent malignant EC cells from mouse 
teratocarcinomas provided the basis for the derivation of 
embryonic stem (ES) cells from explants of mouse 
blastocysts independently [4,5]. Indeed, mouse EC and ES 
cells closely resemble one another, expressing similar 
markers and, in some cases, similar developmental 
potentials, although a report of germ line derivation from 
mouse EC cells in chimeras [6] has never been conﬁ  rmed.
Pluripotent cells in the embryo - inner cell mass cells
At the morula stage, totipotent cells start to specialize as 
they form the blastocyst, comprising an outer layer of 
cells, the trophectoderm (TE), and a group of pluripotent 
cells, the ICM. While the TE will develop into placental 
tissues, the ICM gives rise to all cells of the embryo 
proper as well as several extraembryonic tissues. Th  e 
earliest factors known to regulate the formation of 
pluripotent ICM cells are OCT4 and NANOG [7-9]. 
Without OCT4, epiblast cells fail to form and ES cells 
cannot be derived, while NANOG is required for the 
germline formation [7-9].
Recent studies in the laboratory mouse have provided 
insights into the molecular mechanisms and key factors 
regulating the speciﬁ  cation of ICM and TE lineages. At 
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their position and polarity [10]. In outside cells, Yap, the 
co-activator for transcription factor Tead4, localises in 
the nucleus and increases Tead4 activity. Tead4 subse-
quently activates the TE master factor Cdx2, which 
determines the cell fate [10]. Embryos lacking either 
Tead4 or Cdx2 fail to produce functional trophecto-
dermal tissue but ICM cells remain intact and ES cells 
can be derived [11,12]. Th   e dominance of Cdx2 suppres-
ses Oct4 expression in the outer cells and restricts its 
expression in the inner cells, which become ICM cells at 
the blastocyst stage. Th  us, the counter-activity between 
Oct4 and Cdx2 allows the segregation of the ﬁ  rst two 
embryonic lineages [13]. It is noteworthy that this 
mechanism might be speciﬁ  c to mouse as in both rhesus 
monkey and human, the expression of NANOG is 
reported to be restricted to the ICM, but OCT4 was 
detected in TE as well as ICM cells [14].
Embryonic stem cells and species diff  erences
Although human ES cells were not derived until 1998 
[15], studies of EC cells from human testicular cancers 
demonstrated signiﬁ  cant diﬀ  erences between mouse and 
human EC cells and, by implication, ES cells [16-19]. 
Most notably, the cell surface antigens SSEA1 and SSEA3 
and 4 are expressed diﬀ  erently: mouse EC and ES cells 
are SSEA1(+)/SSEA3(-)/SSEA4(-), whereas human EC 
cells are SSEA1(-)/SSEA3(+)/SSEA4(+). Th  is  surface 
antigen phenotype of human EC cells is similar to that of 
human ES cells [15,20] and human ICM cells [21]. A large 
panel of surface antigen markers and characteristic gene 
expression patterns for human ES cells has now been 
identiﬁ  ed [20]. A further distinction between human and 
mouse ES cells, which was also evident in EC cells, is the 
capacity of human EC and ES cells to generate tropho-
blastic cells [16]. Th  is does not usually occur in mouse 
EC and ES cells, except after genetic manipulation [13]. 
Especially in the mouse, a clear distinction between ES 
cells and epiblast stem cells is being made [22-24]. Recent 
work with human induced pluripotent stem (iPS) and ES 
cells has produced cells more similar to mouse ES cells by 
maintenance in low oxygen conditions, or overexpression 
of  OCT4,  KLF4 and KLF2 and inhibition of glycogen 
synthase kinase 3 and mitogen activated protein kinase 
[25,26]. Th  ese culture conditions with physiological 
oxygen levels (5%) are able to maintain more naïve ES 
cells [26]. However, it remains to be seen if this reduction 
of oxidative stress is important for the use of pluripotent 
stem cells in therapeutic applications.
Inducing pluripotent stem cells from somatic cells
The history of reprogramming
Th  rough early embryonic development and cellular 
diﬀ   er  entiation, cells progressively lose developmental 
potency and choose a speciﬁ  c fate [27]. However, the 
seminal somatic cell nuclear transfer studies of Briggs 
and King [28] showed that blastula cell nuclei retain the 
genetic information required for pluripotency when 
injected into enucleated frog oocytes. Th  is  phenomenon 
was investigated further by Gurdon and Uehlinger [29], 
who demonstrated that even more diﬀ  erentiated intes-
tinal cells were capable of directing development into 
adult frogs following somatic cell nuclear transfer, albeit 
at low eﬃ   ciency (approximately 1%). Th   ese early cloning 
experiments proved that nuclei from terminally diﬀ  er  en-
tiated cells are capable of generating viable cloned 
animals, and formed the basis of later mammalian clon-
ing experiments [30].
Th  e creation of the ﬁ   rst cloned sheep, ‘Dolly’, by 
Wilmut and colleagues [30] together with many other 
later successful mammalian cloning attempts convin-
cingly demonstrated that the developmental restrictions 
established during diﬀ  erentiation are due to reversible 
changes in the epigenome, rather than to permanent 
modiﬁ  cations to the genome [31]. Fusing somatic cells 
with ES cells or exposing them to EC cell extracts can 
also generate cells with pluripotent phenotypes [32,33]. 
Th   us, the cytoplasm of the oocyte and pluripotent stem 
cells must contain factors necessary for reprogramming. 
Th   ese studies indicate that key factors that are important 
for pluripotency within germ cells, early embryos and ES 
cells may also have the reprogramming ability.
Studies with somatic cells demonstrated that one could 
redirect cell fate by forced expression of a single lineage-
speciﬁ  c transcription factor. Weintraub and colleagues 
[34] found that overexpression of MyoD is suﬃ   cient to 
convert ﬁ  broblasts into muscle cells, while mature B cells 
can be reprogrammed into macrophages by enforced 
expression of C/EBPα or C/EBPβ within 3 to 4 days [35]. 
Th  ese studies highlighted the possibility that trans-
diﬀ  erentiation or even dediﬀ  erentiation may be mediated 
by a few deﬁ  ned factors.
Induced pluripotency with key factors
In 2006, the ground breaking work by Takahashi and 
Yamanaka [36] demonstrated that forced expression of 
four ES cell factors (Oct4, Sox2, cMyc, and Klf4) in ﬁ  bro-
blast cells can reprogram them to a pluripotent state. Th  e 
most eﬃ   cient method to make iPS cells is through viral 
transduction due to their high integration eﬃ   ciency 
[37,38]. In properly reprogrammed iPS cells, the trans-
gene driven by the viral promoter should be completely 
silenced [39]. Failure of silencing indicates incomplete 
reprogramming and raises the danger of carcinogenesis 
by the oncogene cMyc [39]. To avoid insertional 
mutagenesis and transgene reactivation, asso  ciated with 
the viral approach, other methods that do not alter the 
genome have been developed, such as non-integrating 
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PiggyBac transposon system [42,43]. Transgene-free iPS 
cells were successfully derived but with lower eﬃ   ciency. 
Th  e most attractive approach may be using permeable 
recombinant proteins [44-46], as this elimi  nates the 
possibility of genome alteration by introduced foreign 
DNA. Th   is would also allow the dosage to be controlled 
and the exposure time of each factor optimised, although 
this method has not been widely successfully applied.
Molecular mechanisms of reprogramming
Re-establishing pluripotency in a somatic cell is a 
complicated process. Th   e most important changes 
include the activation of an ES-cell-speciﬁ  c transcription 
network, re-setting the epigenetic landscape, alteration 
of the cell cycle signature and overcoming the DNA 
damage response triggered by these drastic changes.
ES-cell-specifi  c transcription factors and transcription 
network
Th   e four reprogramming factors discovered by Takahashi 
and Yamanaka, Oct4, Sox2, Klf4 and cMyc, all have vital 
roles in early embryogenesis and ES cells [36]. Th  e  POU 
domain transcription factor Oct4 is required for the 
pluripotency of ICM cells and ES cells and is an essential 
factor in most reprogramming experiments [7]. Although 
in one recent report the nuclear receptor Nr5a2 was able 
to replace Oct4, the underlying mechanism appeared to 
be that Nr5a2 activates Oct4 and Nanog by binding to 
their promoters and upregulating their expression [47]. A 
protein interaction study in mouse ES cells showed that 
Oct4 binds to as many as 92 proteins. Many of these are 
only expressed by ES cells, but some are ubiquitously 
expressed in all cells, such as the nucleosome remodelling 
and deacetylase (NuRD) complex [48]. Th  e cellular 
protein environment can have a signiﬁ  cant inﬂ  uence on 
reprogramming. For example, when fusing a somatic cell 
with an ES cell, or transfering its nucleus into an oocyte, 
where many OCT4 binding partners naturally exist, 
reprogramming is much quicker and more eﬃ   cient 
[32,49]. By choosing adult cell types that express more 
OCT4 interacting proteins, such as neural stem cells and 
melanocytes where SOX2, a Sry-related high mobility 
group box transcription factor, is present, one can obtain 
iPS cells with higher eﬃ     ciency and in a shorter time 
frame [50,51].
In mouse ES cells, it has been shown that Sox2 closely 
works with Oct4 to regulate the transcription of key 
pluripotency genes, including Oct4, Sox2 and Nanog [52]. 
Without Sox2, ES cells cannot eﬀ  ectively activate the Oct-
Sox enhancers. However, higher levels of Oct4 were able to 
compensate for the absence of Sox2 and maintain the ES 
cell phenotype [52]. During reprogramming of mouse 
ﬁ   broblast cells, Sox2 can be replaced by trans  forming 
growth factor-β inhibitors, which have been shown to 
induce both Nanog and cMyc expression [53,54]. Th  us,  it 
appears that Oct4 could work with factors other than Sox2 
to achieve cellular repro  gramming.
Th   e Krüppel-like zinc ﬁ  nger transcription factor Klf4 is 
highly expressed by mouse ES cells and can cooperate 
with the Oct4-Sox2 complex to activate certain ES-cell-
speciﬁ  c genes such as Lefty1 [55]. It plays an important 
role in the pluripotency circuitry by regulating the 
expression of Sox2 and Nanog [56,57]. By overexpressing 
Klf4, mouse epiblast derived stem cells (epistem cells) can 
be returned to the naïve ES cell state [58]. Similarly, 
increasing the expression of KLF4 and OCT4 or KLF4 
and KLF2 enabled human ES cells and iPS cells to exhibit 
mouse ES cell characteristics, including the ability to 
grow in leukemia inhibitory factor (LIF) and 2i (ERK1/2 
and glycogen synthase kinase 3 inhibitors) as well as the 
activation of both X chromosomes [25]. iPS cells 
reprogrammed using Oct4,  Sox2 and Klf4 but without 
cMyc showed lower tumorigenicity [59]. Th  e above 
evidence suggests that Klf4 can prompt cells to acquire a 
more authentic and naïve ES cell phenotype.
cMyc is an oncogene and seems to act as a catalyst in 
the reprogramming process as it can signiﬁ  cantly 
increase the eﬃ   ciency of iPS cell generation [59]. In ES 
cells, cMYC was found to occupy promoters of active 
genes and ES-cell-speciﬁ  c microRNAs (miRNAs), includ-
ing miR-291-3p, miR-294, miR-295, miR-141, miR-200, 
and miR-429 [57,60,61]. Overexpression of these 
miRNAs either promoted iPS cell generation or reduced 
mouse ES cell diﬀ  erentiation [60,61]. cMYC can recruit 
multiple chromatin remodellers, such as histone acetyl-
transferase GCN5 and histone demethylase Lid, to create 
an open chromatin state. Th  is allows the ectopically 
expressed ES cell transcription factors to activate their 
target genes more easily [62]. Th   e negative side of cMYC’s 
action is tumorigenecity [59]. Th  us, iPS cells created 
using cMyc need to be carefully scrutinised to ensure the 
silence of this oncogene.
NANOG and LIN28 can replace KLF4 and cMYC to 
reprogram human ﬁ  broblast cells to iPS cells [38]. Nanog 
is a core member of the pluripotency circuitry [57] and 
constitutive expression is suﬃ     cient to support self-
renewal of mouse ES cells in the absence of LIF [8]. 
Nanog is also required for germline development [63]. 
Although not absolutely required for reprogramming, 
including  Nanog increased the eﬃ   ciency  of  iPS 
generation [64].
LIN28 is an evolutionarily conserved RNA binding 
protein highly enriched in mouse and human ES cells 
[20,65]. Its function in reprogramming will be discussed 
in more detail later in the section on miRNAs.
Studies in mouse ES cells revealed that the promoter 
region of actively transcribed genes was often occupied 
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Moreover, these factors can self-regulate to reinforce the 
undiﬀ   erentiated state. Diﬀ   erent combinations of 
transcription factors may control distinct subgroups of 
genes [57]. Th   us, to activate the entire ES cell transcrip-
tome, not only is the cooperation of key factors (namely 
OCT4, SOX2, KLF4 and cMYC) required, but their levels 
and ratio of expression are also critical [66]. Two very 
recent publications reported that reprogramming factors 
can also orchestrate a mesenchymal to epithelial 
transition, which is important for the initiation stage of 
repro  gramming [67,68]. Down-regulation of epithelial-
speciﬁ  c factors, such as ECADHERIN, PAR3 and CRB3, 
suppressed the formation of iPS colonies [68], while 
suppression of transforming growth factor-β signalling, 
which is important for epithelial to mesenchymal 
transition, improved reprogramming eﬃ   ciency [67].
Epigenetics
Th  e chromatin and DNA modiﬁ  cation machinery play 
critical roles during reprogramming as the epigenetic 
landscape of a somatic cell needs to be completely 
reshaped to ES-cell-like states. Th   e epigenome of ES cells 
is characterised by the demethylation of the promoter 
regions of key pluripotency transcription factors, such as 
Oct4,  Sox2 and Nanog, as well as bivalent chromatin 
modiﬁ  cations on developmentally important transcrip-
tion factors [69]. Th   is ensures a high level of expression 
of the core factors that maintain pluripotency. At the 
same time cells reside in a poised state, ready to diﬀ  er-
entiate in response to developmental signals [69].
During reprogramming, the genome loci occupied by 
histone H3 lysine 4 trimethylation (H3K4me3) and 
histone H3 lysine 27 trimethylation, which are commonly 
associated with active and repressive gene expression, 
respectively, appears to change in accordance with the 
dediﬀ   erentiation process. For example, H3K4me3 
marking was lost from promoter regions of mouse 
embryonic ﬁ  broblast-speciﬁ   c genes, but increased 
signiﬁ    cantly on the promoters/enhancers of the ES-cell-
speciﬁ  c genes Fgf4, Oct4 and Nanog [70]. Moreover, the 
DNA methylation was erased at promoters of pluri-
potency genes in fully reprogrammed cells but not in 
mouse embryonic ﬁ  broblasts or partially reprogrammed 
cells [70]. To date, many cell types, including some cancer 
cells, have been shown to be amenable for repro-
gramming, reﬂ   ecting the plasticity of the epigenome 
[51,64,71,72]. Diﬀ  erent cell types may possess diﬀ  erent 
degrees of plasticity; compared to skin ﬁ  broblast cells, 
epithelial cell types, such as keratinocytes, liver and 
stomach cells, can be converted to iPS cells with higher 
eﬃ   ciency [72,73]. In addition, a hierarchy of epigenetic 
states may correlate with a cell’s diﬀ  erentiation stage. It 
was found that in the hematopoietic lineage, stem and 
progenitor cells give rise to iPS cells much more 
eﬃ   ciently  than  terminally  diﬀ  erentiated B and T cells 
[74]. Manipulating the DNA and chromatin modiﬁ  cations 
can greatly facilitate iPS cell formation. Th  e DNA 
methyltransferase inhibitor 5’-azacytidine and the 
histone deacetylase inhibitor valproic acid increased the 
reprogramming eﬃ   ciency 5-fold and more than 100-fold, 
respectively [75]. BIX-01294, an inhibitor of the G9a 
histone methyltransferase, was able to substitute cMyc to 
induce pluripotency from neural stem cells together with 
Oct4 and Klf4 [76].
Two recent studies observed that early passage iPS cells 
still retain some degree of somatic cell memory, which 
can inﬂ  uence the diﬀ  erentiation preference of these cells 
[77,78] . However, these remaining epigenetic memories 
appeared to attenuate after continuous in vitro culture 
[77,78]. In addition, some mouse iPS cell lines displayed 
aberrant silencing of imprinted genes such as the Dlk1-
Dio3 cluster. Th  ese lines showed poor contribution to 
chimeric animals and were not germline competent 
[79,80]. Th  e ability of germline transmission is also 
inﬂ  uenced by the combination of reprogramming factors. 
Mouse iPS cells generated by Oct4, Sox2, Klf4 and Tbx3 
were found to contribute to the germ tissue with higher 
eﬃ   ciency compared to iPS cells reprogrammed by Oct4, 
Sox2, and Klf4 or Oct4, Sox2, and Esrrb [81]. Imprinting 
abnormalities were found in human iPS cells, including 
the biallelic expression of H19 and KCNQ10T1 [82]. Th  e 
Fragile X syndrome gene (FX) was active in ES cells 
derived from embryos with the FX mutation but 
remained silenced in iPS cells reprogrammed from FX-
ﬁ  broblast cells [83]. Th   us, if iPS cells and their derivatives 
are to be used to model human diseases or in therapeutic 
applications, several aspects need to be carefully 
evaluated: the tissue origin and passage number; the 
reprogramming factors used; the status of imprinted 
genes; and the histone modiﬁ   cation of disease-related 
genome loci.
microRNAs and reprogramming
miRNAs are approximately 22-nucleotide RNAs that 
bind to complementary sequences in the 3’ untranslated 
regions of protein coding mRNAs to regulate their 
degradation or translation [84]. As important modulators 
of developmental timing and stem cell diﬀ  erentiation, 
they have, unsurprisingly, also been implicated in 
reprogramming. Th  e well-known Let-7 family miRNAs 
are ubiquitously expressed in somatic cells and up-
regulated upon ES cell diﬀ  erentiation.  Th  eir mRNA 
targets include those encoding cell cycle regulators such 
as K-RAS, cMYC, CDC25A, cyclinD1, and stem cell 
factors HMGA2, Mlin-41 and IMP-1 [82,85]. Lin28 is an 
ES-cell-speciﬁ  c factor whose major function is to keep 
let-7 miRNAs at low level by promoting their degradation 
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colleagues [64] showed that overexpression of Lin28 
shortened the cell cycle in monoclonal B cells and sped 
up iPS cell generation. In another report, the ES-cell-
speciﬁ  c miRNA miR-294 increased the eﬃ   ciency of iPS 
cell generation by approximately tenfold when introduced 
together with Oct4, Sox2 and Klf4, but not when cMyc 
was present [60]. Th  e authors then found that miR-294 
was a downstream target of cMyc [60]. Interestingly, 
using a green ﬂ  uorescent protein (GFP) reporter driven 
by the Oct4 promoter, most colonies from the Oct4, Sox2, 
Klf4 and miR-294 group were positive for GFP expres-
sion, indicating that they are more homogenous iPS cell 
colonies. In contrast, cMyc signiﬁ   cantly increased the 
number of GFP-positive as well as GFP-negative colonies 
when added together with Oct4, Sox2, and Klf4 [60]. Th  is 
study suggests that ES-cell-speciﬁ  c miRNAs are able to 
ﬁ  ne tune the reprogramming process and may be useful 
to reduce the heterogeneity in iPS cells.
DNA damage
Th  e cellular stress imposed by reprogramming can 
trigger the DNA damage response and subsequently 
result in cell cycle arrest and senescence. Only a few cells 
were able to overcome this barrier and become iPS cells. 
Th  is may be the reason why the eﬃ   ciency  of  repro-
gramming is extremely low. Several studies have 
demonstrated that when key components (such as p53 
and p21) of the DNA damage machinery were deleted, 
the rate of iPS cell generation is signiﬁ  cantly increased 
[88-94]. Th  e detailed mechanism will be discussed by a 
separate review in this issue. It has been shown recently 
that vitamin C supplementation can improve reprogram-
ming eﬃ     ciency by alleviating p53-induced cell senes-
cence and synergizing with epigenetic regulators [95]. 
However, it is dangerous to obtain rapid reprogramming 
at the cost of inappropriate suppression of DNA damage 
pathways. SV40 large T can disrupt the nuclear DNA-
repair foci [96]. When it was added together with the 
four factors to reprogramme human ﬁ  broblast cells, iPS 
cell colonies emerged after 8 days but many of those iPS 
cells gained chromosomal abnormalities [97]. Th  us, the 
intricate balance between safeguarding genome integrity 
and changing cell fate must be carefully maintained 
during reprogramming.
Future challenges
By elucidating the mechanisms of how pluripotency 
factors interact with one another and with the genome, it 
should be possible to devise means to signiﬁ  cantly 
improve reprogramming eﬃ   ciency and speed. New inter-
action partners or pathways might provide explanations 
to species diﬀ  erences and provide the means to a deﬁ  ned 
in vitro culture of pluripotent cells. It remains to be seen 
whether human ES cells resemble an ICM or epiblast like 
stage, and whether or not that has any impact on their 
clinical applicability.
Several articles have reported that iPS cells are notably 
distinct from ES cells in terms of their gene expression, 
epigenetic proﬁle, proliferative capacity and the suscep-
tibility of their diﬀ  erentiated progeny to cellular senes-
cence and apoptosis [82,83,98-100]. Th  ese diﬀ  er  ences 
need to be clearly deﬁ  ned and may become of importance 
if developmental research should be translated into the 
clinic. Th  e  deﬁ  nition of the cells in terms of pluripotency 
markers and the reproducibility of cell culture conditions 
will have a major impact on possible future therapeutical 
applications. Th  ere is a need for standardization in 
clinical protocols, which proﬁ  ts from fully deﬁ  ned media 
conditions allowing reproducible growth of pluripotent 
cells. Initial requirements, such as good manufacturing 
practice, are the same for human ES cells and human iPS 
cells [101]. However, iPS cells are certainly a step further 
away from clinical application than ES cells, as more 
parameters are yet to be characterized. First among these 
are issues of safety and eﬃ   cacy. Th   e earliest methods for 
the derivation of iPS cells used viral vectors, which may 
induce insertional mutagenesis and transgene reactiva-
tion. Alternative methods for inducing pluripotency 
without the use of gene insertion have been reported, 
though their eﬃ   ciency needs improvement. Other safety 
criteria, such as long-term karyotypic stability, appro-
priate in situ localization, and potential diﬀ  erentiation of 
somatic cells derived from iPS cells, are to be investigated 
[102,103].
Conclusions
Ultimately, understanding of the underlying mechanisms 
of pluripotency will be able to guide the way to a safe and 
new cell-based medicine. Th  e modelling of disease and 
normal development, if well understood, provides the 
chance to design completely new treatment modalities. 
Being autologous cells, iPS cells especially allow for a new 
individualised approach and are able to create a cell 
model as well as a cell source for each and every person.
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